Bijuva (Estradiol/Progesterone)

Prescription Required
Brand
Dose Size & Price Qty
1mg / 100mg
  • Description
  • Reviews (0)
  • Related Products
  • Related Conditions

Fact Table

Fact Table
Formula C18H24O2 (estradiol); C21H30O2 (progesterone)
License FDA approved (NDA 210132; initial U.S. approval 2018); Health Canada approved (NOC 2020)
Bioavailability Absolute bioavailability not stated; oral absorption subject to first-pass metabolism; food increases progesterone exposure
Legal status Prescription only (Rx only)
Chemical Name Estradiol: estra-1,3,5(10)-triene-3,17ß-diol; Progesterone: pregn-4-ene-3,20-dione
Elimination half-life Estradiol ~26–28 hours; progesterone ~9–10 hours after repeat dosing
Dosage (Strength) 0.5 mg estradiol/100 mg progesterone and 1 mg estradiol/100 mg progesterone oral capsules; one capsule each evening with food
Pregnancy Not indicated for use in pregnancy; no data with BIJUVA in pregnant women
Brands Bijuva (Mayne Pharma; registered trademark of TherapeuticsMD, Inc., used under license)
Protein binding Estradiol largely bound to SHBG and albumin; progesterone ~96–99% bound to serum proteins
PubChem CID 5757 (estradiol); 5994 (progesterone)
MedlinePlus a601041
ChEBI 16469 (17ß-estradiol); 17026 (progesterone)
ATC code G03FA04
DrugBank DB00783 (estradiol); DB00396 (progesterone)
KEGG D04459 (progesterone and estradiol); D00105 (estradiol); D00066 (progesterone)
Routes of administration By mouth (oral capsules)

Bijuva (estradiol and progesterone) is a prescription hormone therapy capsule used to treat moderate to severe hot flashes caused by menopause. It combines two hormones, estradiol, a form of estrogen, and progesterone, in one capsule, which helps relieve menopausal symptoms while also protecting the lining of the uterus. It is approved for women who still have a uterus and are experiencing menopausal symptoms.

Directions

Take one Bijuva capsule by mouth every evening with food. Your doctor or healthcare provider will determine the appropriate starting dose. Every 3 to 6 months, your doctor may reassess whether you still need the medication and may try to reduce or stop the dose. Do not stop taking Bijuva without consulting your doctor first.

Ingredients

The active ingredients in Bijuva are estradiol and progesterone. Inactive ingredients include lauroyl PEG-32 glycerides, gelatin (Type B bovine), glycerin, water, titanium dioxide, FD and C Red No. 40, ethanol, ethyl acetate, propylene glycol, polyvinyl acetate phthalate, isopropyl alcohol, polyethylene glycol, ammonium hydroxide, medium-chain triglycerides, and soybean lecithin.

Cautions

Before using this medication, you may want to consult a healthcare provider about the following:

  • Any existing health conditions
  • Any allergies
  • A list of all medications currently being taken

Bijuva increases the risk of blood clots, stroke, and heart attack. Contact your doctor if you experience chest pain, shortness of breath, sudden weakness, or leg pain and swelling.

Using estrogen-containing medications may increase the risk of breast cancer. Talk to your doctor about your personal risk and have regular breast exams and mammograms.

If you are taking thyroid replacement medication, your doctor may need to monitor your thyroid levels more closely while on Bijuva.

Bijuva may cause fluid retention. Let your doctor know if you have heart, kidney, or liver problems.

Monitor your blood pressure regularly while taking Bijuva.

Tell your doctor if you have asthma, diabetes, epilepsy, migraines, or a history of gallbladder disease, as Bijuva may worsen these conditions.

Contraindications

Avoid taking or using this medication if any of the following apply:

  • Undiagnosed abnormal genital bleeding
  • Breast cancer or a personal history of breast cancer
  • Estrogen-dependent tumors
  • Active or history of deep vein thrombosis (DVT) or pulmonary embolism (PE)
  • Active or history of arterial thromboembolic disease, such as stroke or heart attack
  • Known hypersensitivity, anaphylaxis, or angioedema to Bijuva or any of its ingredients
  • Liver disease or dysfunction
  • Known clotting disorders, including protein C, protein S, or antithrombin deficiency

Side Effects

Common side effects of Bijuva include:

  • Breast tenderness
  • Headache
  • Nausea
  • Vaginal bleeding
  • Vaginal discharge
  • Pelvic pain

Bijuva may increase the risk of serious conditions, including blood clots, stroke, heart attack, and breast cancer. Long-term use may also raise the risk of gallbladder disease.

Seek emergency medical help if you experience chest pain, sudden severe headache, vision changes, calf pain or swelling, or unusual vaginal bleeding.

Frequently Asked Questions about Bijuva


What is Bijuva used for?

Bijuva is a prescription oral hormone therapy used after menopause in women who still have a uterus to treat moderate to severe hot flashes, also called vasomotor symptoms.


What is in Bijuva, and why does it combine two hormones?

Bijuva contains estradiol, an estrogen, and progesterone, a progestogen. The estrogen helps relieve menopausal hot flashes, and the progesterone component is included for women with a uterus because progestogens are used to lower the chance of cancer of the uterine lining when estrogen is given.


How is Bijuva taken?

The usual directions are one capsule by mouth each evening with food. The current prescribing information says therapy generally starts with the 0.5 mg estradiol/100 mg progesterone strength, with dose adjustments based on response, and treatment should be re-evaluated regularly with attempts to taper or stop at 3- to 6-month intervals.


What strengths are available?

Bijuva capsules are available in two strengths: 0.5 mg estradiol/100 mg progesterone and 1 mg estradiol/100 mg progesterone.


How soon can Bijuva start helping hot flashes?

In clinical studies, both approved strengths reduced the frequency and severity of moderate to severe hot flashes compared with placebo by Week 4 and again by Week 12, so improvement may begin within the first month, though timing varies by person.


What are the most common side effects?

The most commonly reported side effects are breast tenderness, headache, nausea, vaginal bleeding, vaginal discharge, and pelvic pain.


What are the most important serious risks?

Estrogen plus progestogen therapy can increase the risk of blood clots, stroke, heart attack, and breast cancer, and postmenopausal vaginal bleeding should be evaluated because it can be a warning sign of uterine cancer. Bijuva should not be used to prevent heart disease, heart attacks, strokes, or dementia.


Who should not take Bijuva?

It should not be used by women who have had a hysterectomy, or by anyone with unexplained genital bleeding, current or past breast cancer, estrogen-dependent cancer, active or prior DVT or pulmonary embolism, active or prior stroke or heart attack, liver disease, known thrombophilic disorders, or allergy to the product.


What happens if a dose is missed?

If you miss an evening dose, take it with food as soon as you can unless it is within 2 hours of the next evening dose. In that case, skip the missed dose and resume the regular schedule.


Can Bijuva be used during pregnancy or breastfeeding, and are there important interactions?

Bijuva is not indicated during pregnancy. Its hormones can pass into breast milk and may reduce milk production. It can also interact with CYP3A4-affecting products, so medicines such as rifampin, carbamazepine, phenobarbital, St. John’s wort, ketoconazole, clarithromycin, ritonavir, and even grapefruit juice can change hormone levels. Store it at room temperature.

No Reviews